Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for VolitionRX Limited (VNRX : AMEX)

• Company Description    Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer types. The Company's development activities are primarily centered in Belgium. Volition RX Ltd is based in Singapore. Number of Employees: 85

• Price / Volume Information    Yesterday's Closing Price: $0.68 Daily Weekly Monthly 20 Day Moving Average: 301,502 shares Shares Outstanding: 103.98 (millions) Market Capitalization: $70.71 (millions) Beta: 1.20 52 Week High: $0.94 52 Week Low: $0.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.09% 9.82% 12 Week 38.78% 16.73% Year To Date 13.33% 6.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1489 WEST WARM SPRINGS ROAD SUITE 110 - HENDERSON,NV 89014 USA ph: 646-650-1351 fax: 65 32 8172 5651 investorrelations@volition.com http://www.volition.com

• General Corporate Information    Officers Cameron Reynolds - President; Chief Executive Officer and Director Terig Hughes - Chief Financial Officer and Treasurer Timothy I. Still - Director Guy Innes - Director Alan Colman - Director Peer Information VolitionRX Limited (CORR.) VolitionRX Limited (RSPI) VolitionRX Limited (CGXP) VolitionRX Limited (BGEN) VolitionRX Limited (GTBP) VolitionRX Limited (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 928661107 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 103.98 Most Recent Split Date: (:1) Beta: 1.20 Market Capitalization: $70.71 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 54.02 EPS Growth vs. Year Ago Period: 40.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 43.02% vs. Previous Quarter: 28.13% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -220.07 12/31/24 - -197.63 Current Ratio 06/30/25 - - 03/31/25 - 0.40 12/31/24 - 0.52 Quick Ratio 06/30/25 - - 03/31/25 - 0.40 12/31/24 - 0.52 Operating Margin 06/30/25 - - 03/31/25 - -1,835.37 12/31/24 - -2,183.64 Net Margin 06/30/25 - - 03/31/25 - -1,835.37 12/31/24 - -2,183.64 Pre-Tax Margin 06/30/25 - - 03/31/25 - -1,853.55 12/31/24 - -2,208.91 Book Value 06/30/25 - - 03/31/25 - -0.29 12/31/24 - -0.28 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©